| Alchemab Therapeutics East Side, Office 1.02 Kings Cross London N1C 4AX |
Meditrina Building 260 Babraham Research Campus Cambridge CB22 3AT |
© 2021 Alchemab. All rights reserved.
| Alchemab Therapeutics East Side, Office 1.02 Kings Cross London N1C 4AX |
Meditrina Building 260 Babraham Research Campus Cambridge CB22 3AT |
© 2021 Alchemab. All rights reserved.
Alchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer
/in Press releases /by resilienceIndustry Veteran Brings Experience and Proven Track Record of Success Plans for Management Team Expansion and Global Reach Through Newly Established U.S. Office Cambridge, UK and Boston, Massachusetts, June 22, 2021 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, today announced the appointment of […]
Alchemab to collaborate with AstraZeneca to use Alchemab’s drug discovery platform for prostate cancer study
/in Press releases /by resilienceCambridge, UK, 5 May 2021 – Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has formed a collaboration with AstraZeneca to accelerate prostate cancer research.
Alchemab raises £60 million ($82 million) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
/in Press releases /by resilienceCambridge, UK, 15 April 2021 – Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.